The US FDA split the difference with its external advisors on the regulatory options for Takeda Pharmaceuticals USA Inc.’s gout drug Uloric (febuxostat), requiring the cardiovascular death label warning and restricted indication advocated by its advisory committee but not the formal Risk Evaluation and Mitigation Strategy (REMS) that agency staff suggested was unworkable.
Nevertheless, the regulatory actions highlighted by FDA, including a new postmarketing commitment by Takeda to monitor febuxostat utilization after the...




